THE SWISS MALARIA GROUP
MEMBERS

ACINO PHARMA
Acino is a Swiss Pharmaceutical company headquartered in Zurich. With a clear focus on selected markets in the Middle East, Africa, the CIS Region, and Latin America, we are operating in some of the dynamic countries in the world. Our in-depth knowledge of our markets enables us to adapt to local needs, however challenging.

For over 20 years we have developed malaria products with considerable investment and will further strengthen our contribution as new treatment options become available.

www.acino-pharma.com

BIOVISION
Biovision is a Swiss organization founded with the aim of sustainably improving life for people in Africa while conserving the environment as the basis for all life. Biovision is engaged in the field of information and supports projects in Switzerland which show how each individual can contribute to an environmentally and socially responsible development in the world. In its Stop malaria initiative, Biovision has pilot projects in Kenya and Ethiopia that are using environmentally friendly methods – so-called «Integrated Vector Management» (IVM) – in order to tackle malaria. These pilot projects run by Biovision are demonstrating that environmentally-friendly and cost-effective methods supported by the local community can effectively control malaria.

www.biovision.ch

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)
Research at the CHUV is geared towards public health in developing countries. The CHUV is also part of the Swiss Institute for Vaccine Research which was launched on December 5, 2007. This Institute encompasses the principal aspects of vaccine research to fight the three main infectious diseases: HIV/AIDS, tuberculosis and malaria. It encourages cooperation between scientists working in the field of HIV, malaria, tuberculosis, influenza and cancer vaccine development in Switzerland. The CHUV has a substantial clinical trial infrastructure that is available for vaccine research.

www.chuv.ch

DRUGS FOR NEGLECTED DISEASES INITIATIVE (DNDi)
DNDi is a not-for-profit research and development organization working to deliver new treatments for neglected diseases. Since its inception in 2003, DNDi has delivered six new treatments to patients in need, notably for malaria, sleeping sickness, leishmaniasis, and Chagas disease, and is working on other new treatments for these diseases as well as specific helminth infections and paediatric HIV. The two treatments developed for malaria are the fixed-dose combinations ASA Q and ASM Q. ASA Q, launched in 2007, was developed in partnership with the French pharma-ceutical company Sanofi; ASM Q was launched in 2008 thanks to a partnership with the Brazilian public pharmaceutical company Farmanguinhós.

www.dndi.org
NOVARTIS
Focused on access, treatment, R&D and capacity building, the Novartis Malaria Initiative is one of the healthcare industry's largest access to medicine programs measured by the number of patients reached annually. Novartis launched the first WHO prequalified fixed-dose artemisinin-based combination therapy. Since 2001, the Novartis Malaria Initiative has delivered more than 750 million antimalarial treatments, including 300 million pediatric treatments, without profit, to more than 60 countries. Over the last few years, Novartis and partners have discovered two new classes of compounds with great antimalarial potential. Thank you to all our partners for their contribution to this extraordinary achievement and for supporting our efforts toward a malaria-free world.

www.novartis.com

FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS (FIND)
FIND is dedicated to developing affordable, easy to use and cutting edge diagnostic tests that save lives in the poorest areas of the world. In addition to malaria, the not-for-profit organization works on tuberculosis, sleeping sickness, leishmaniasis and Chagas disease. Beyond developing new tests, Fi ND also works with partners to ensure that diagnostics can be used effectively in the field. Since inception in 2003, Fi ND has already brought six new technologies into widespread use, using its public-private model.

www.finddiagnostics.org

MEDICUS MUNDI SWITZERLAND (MMS)
Medicus Mundi Switzerland, the network health for all, is a network of around 50 Swiss organisations working in the field of international health. Medicus Mundi Switzerland promotes the sharing of knowledge and know-how among its members and advocates for universal access to health and health care as a fundamental human right. Some of the members provide advice and support to partner organisations in their fight against malaria.

www.medicusmundi.ch

MEDICINES FOR MALARIA VENTURE (MMV)
MMV, a not-for-profit public-private partnership, was established as a foundation in Switzerland in 1999. Our mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs. Our vision is a world in which these innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate this terrible disease.

www.mmv.org

NOVARTIS PHARMACEUTICALS
www.novartis.com
PATH – PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH
PATH is a leader in efforts to control and eliminate malaria nationally, regionally, and ultimately to eradicate it worldwide. With our unparalleled portfolio of malaria projects—across vaccines, drugs, diagnostics, and system innovations—we are partnering with countries and organizations around the world to make malaria history.

www.path.org

SOLIDARMED
SolidarMed improves health care for 1.5 million people in southern Africa. In order to effectively prevent malaria, pregnant women receive prophylactic medication and families with children receive insecticide-treated bednets. Over the radio and in village meetings, people from over 300 villages find out how they can effectively protect themselves and their children from malaria. Should a child still fall ill, SolidarMed enables rapid transfer to one of the 16 partner hospitals, where malaria rapid tests quickly bring clarity and well-trained staff effectively treats the infection. In 2015 alone, SolidarMed enabled initial or further training for 1100 nursing staff.

www.solidarmed.ch

SAVE THE CHILDREN
Save the Children helps reducing Malaria which prevents children to develop their full potential and hinders their access to education. The organization has been a leader in providing maternity care, emergency response and basic education in many world regions and will now focus on improving child health and development in Africa, especially Mali. By strengthening the link between health and education sectors, Save the Children aims to reach over 80% of children in Mali by providing seasonal malaria clearance and micronutrient supplementation for a steady start into a healthy life.

www.savethechildren.ch

SWISS AGENCY FOR DEVELOPMENT AND COOPERATION (SDC)
SDC contributes to the fight against malaria through bilateral as well as multilateral cooperation. In partner countries that are highly malaria endemic, SDC backs specific projects that tackle malaria by increasing mosquito-net coverage, strengthening health systems and supporting community-based initiatives. At international level, SDC contributes to the fight against malaria with financial contributions to global initiatives such as the Global Fund to Fight AIDS, Tuberculosis and Malaria and to internationally recognized academic institutions as well as public private partnerships that are driving innovative research and the development of new prevention means, drugs and diagnostic tools.

www.sdc.admin.ch
SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE

The Swiss Tropical and Public Health Institute (Swiss TPH) is active in many fields related to research and malaria control, in particular in the innovation of new concepts and products (vaccines and medicines), the validation of new interventions and the implementation of health system strengthening strategies. A number of large scale programs aim to improve the quality of health care for children. In Tanzania two vaccine candidates show promising results and the Swiss TPH supports the distribution of insecticide treated bed nets for over 15 years.

www.swisstph.ch

SWISS RED CROSS (SRC)

In the international cooperation, the Swiss Red Cross (SRC) aims to improve access to good quality health care for particularly vulnerable and deprived people and communities. In more than 35 countries worldwide. In the fight against malaria our priority is to distribute mosquito nets that are treated with insecticide. Volunteers are key to teach villagers how to correctly use the nets and to refer them to health professionals for treatment when they fall ill.

www.redcross.ch

SYNGENTA

Syngenta is a leading agriculture company helping to improve global food security by enabling millions of farmers to make better use of available resources. Through world class science and innovative crop solutions, our 28,000 people in over 90 countries are working to transform how crops are grown. We are committed to rescuing land from degradation, enhancing biodiversity and revitalizing rural communities. To learn more visit www.syngenta.com and www.goodgrowthplan.com. Follow us on Twitter® at www.twitter.com/Syngenta

Syngenta’s corporate goals include those dedicated to the improvement of health and quality of life. We believe that people around the world deserve to live their lives uninterrupted by mosquito borne disease such as malaria. Syngenta Vector Control delivers this commitment by playing a leading role in the prevention of vector borne disease transmission through its portfolio of mosquito control products and partnerships with professional disease control programs worldwide. We are delivering the advanced tools required to meet today’s challenges in malaria mosquito control and also supporting the development of the next generation of tools through partnerships with the IVCC.

www.syngenta.com